Merck KGaA beats forecasts, with 2010 sales up 20% and net profit leaping 73%

21 February 2011

German drug major Merck KGaA (MRK: DE) this morning announced its full-year 2010 results with 20% year-on-year growth in revenue to 9.291 billion ($12.67 billion), above consensus estimates of 9.24 billion, respectively. Revenues were mainly boosted by the recent 5.1 billion-euro acquisition of Millipore Corp which contributed about 8.4% points increase, positive currency added 3.7 percentage points and the remaining 7.9 percentage points came from organic growth.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK